Iksuda Therapeutics develops next-generation antibody-drug conjugate (ADC ... s vinyl-pyridine-based chemistry reacts with the thiol group on the amino acid cysteine. Cysteines are used to ...
an older ADC that uses a tubulin inhibitor (antimitotic agent) DM1 as its payload. Third, Enhertu’s cysteine-based conjugation process is able to achieve a high drug-to-antibody ratio of around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback